|
| 36791207 | An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. | Sci Transl Med | 2023 |
| 38008801 | Sequential vaccinations with divergent H1N1 influenza virus strains induce multi-H1 clade neutralizing antibodies in swine. | Nat Commun | 2023 |
| 37703367 | Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice. | Sci Adv | 2023 |
| 37871218 | Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo. | Proc Natl Acad Sci U S A | 2023 |
| 37313413 | Group 1 and group 2 hemagglutinin stalk antibody response according to age. | Front Immunol | 2023 |
| 37342504 | Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses. | Front Bioeng Biotechnol | 2023 |
| 37164959 | Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. | NPJ Vaccines | 2023 |
| 36533948 | Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity. | J Virol | 2023 |
| 35169806 | Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. | medRxiv | 2022 |
| 35577631 | Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. | Vaccine | 2022 |
| 35461522 | Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. | Lancet Infect Dis | 2022 |
| 35594401 | Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. | Proc Natl Acad Sci U S A | 2022 |
| 35658571 | Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. | Microbiol Spectr | 2022 |
| 36496417 | Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination. | NPJ Vaccines | 2022 |
| 35284808 | Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. | EClinicalMedicine | 2022 |
| 34942633 | Broadly neutralizing antibodies target a haemagglutinin anchor epitope. | Nature | 2022 |
| 34999208 | A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. | Mol Ther | 2022 |
| 33440898 | Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. | Vaccines (Basel) | 2021 |
| 33593910 | Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. | Proc Natl Acad Sci U S A | 2021 |
| 34868082 | Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. | Front Immunol | 2021 |
| 34707161 | A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. | Nat Commun | 2021 |
| 34580673 | Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. | medRxiv | 2021 |
| 34401874 | Prophylactic Protection Against Respiratory Viruses Conferred by a Prototype Live Attenuated Influenza Virus Vaccine. | Res Sq | 2021 |
| 34696339 | Interaction between NS1 and Cellular MAVS Contributes to NS1 Mitochondria Targeting. | Viruses | 2021 |
| 34544278 | Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. | mBio | 2021 |
| 34603333 | Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. | Front Immunol | 2021 |
| 34485597 | Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. | Mol Ther Methods Clin Dev | 2021 |
| 34773048 | Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. | Sci Rep | 2021 |
| 34078743 | First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. | Sci Transl Med | 2021 |
| 34126773 | An Egg-Derived Sulfated <i>N</i>-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. | mBio | 2021 |
| 33948589 | Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine. | bioRxiv | 2021 |
| 33288923 | A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. | Nat Med | 2021 |
| 31630990 | Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. | Lancet Infect Dis | 2020 |
| 32087122 | Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. | Lancet | 2020 |
| 31694938 | Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. | J Virol | 2020 |
| 31988118 | High-complexity extracellular barcoding using a viral hemagglutinin. | Proc Natl Acad Sci U S A | 2020 |
| 33323511 | H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model. | mBio | 2020 |
| 33096040 | Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. | Immunity | 2020 |
| 33232870 | Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. | EBioMedicine | 2020 |
| 33348607 | A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. | Vaccines (Basel) | 2020 |
| 32743571 | Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate. | bioRxiv | 2020 |
| 32766572 | A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. | bioRxiv | 2020 |
| 32670279 | Current Challenges in Vaccinology. | Front Immunol | 2020 |
| 32359470 | A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. | Mol Ther | 2020 |
| 32493826 | Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. | J Virol | 2020 |
| 31600454 | Is a Universal Influenza Virus Vaccine Possible? | Annu Rev Med | 2020 |
| 30381487 | Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. | J Virol | 2019 |
| 31839997 | Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. | NPJ Vaccines | 2019 |
| 31676387 | Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. | EBioMedicine | 2019 |
| 31375573 | Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase. | J Virol | 2019 |